Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay.

导出 OA

翻译打印收藏纠错

作者： Jingrong,Zhao ^[1] ; Zhelin,Li ^[1] ; Ruchira,Puri ^[1] ; Kelvin,Liu ^[1] ; Israel,Nunez ^[1] ; Liang,Chen ^[2] ; Sika,Zheng ^[1]

作者单位： Division of Biomedical Sciences, School of Medicine, University of California, Riverside, CA 91709, USA. ^[1] Department of Quantitative and Computational Biology, University of Southern California, Los Angeles, CA 90089, USA. ^[2]

关键词 Hnrnpl Ptbp2 Tra2b albendazole artesunate gabexate mesilate mitoxantrone montelukast sodium topotecan hydrochloride trazodone hydrochloride

DOI 10.1016/j.omtn.2021.12.003

PMID 35024243

发布时间 2024-05-29

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Molecular therapy. Nucleic acids

2022年27卷

304-318页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay.

Molecular therapy. Nucleic acids

相似文献

Molecular therapy. Nucleic acids

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Molecular profiling of individual FDA-approved clinical drugs identifies modulators of nonsense-mediated mRNA decay.

Molecular therapy. Nucleic acids

相似文献

Molecular therapy. Nucleic acids

相关期刊

检索历史清除